Characterization of Parthanatos in Breast Cancer: Implications for Prognosis and PARP Inhibitor Resistance.

ABSTRACT: Parthanatos, a novel form of programmed cell death mediated by PARP1 and driven by DNA damage, has not been comprehensively characterized in breast cancer (BC). Given the widespread clinical use of PARP1 inhibitors for treating BRCA-mutant breast cancers, understanding the role of parthanatos is crucial. In this study, we systematically analyzed the role and clinical significance of parthanatos in BC by integrating genomic, transcriptomic, and clinical data. Our analysis revealed significant differential expression of parthanatos-related genes between BC and normal breast tissues, with frequent copy number variations (CNVs) affecting gene expression. At the single-cell level, parthanatos-related genes were primarily expressed in breast cancer cells and macrophages, and genomic instability

SUBMITTER: Tang J 

PROVIDER: S-EPMC12189614 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature